|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 45, 1992-1999, November 2004 Demonstration of reverse fatty acid transport from rat cardiomyocytes
* Gifford Laboratories, Touchstone Center for Diabetes Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400237-JLR200
1 To whom correspondence should be addressed. e-mail: roger.unger{at}utsouthwestern.edu
Fatty acids flow from adipocytes to nonadipose tissues during fasting and exercise and normally are fully oxidized. To determine if nonadipose tissues can export unoxidized FA when FA influx exceeds oxidation, neonatal cardiomyocytes were cultured in 1 µCi 14C-palmitate in the presence of etomoxir to block oxidation. The cells took up and stored 25% of the radioactivity as 14C-triacylglycerol in 12 h, but 4.5% of the label was released in 3 h and comigrated with 14C-palmitate. Both uptake and release of radioactivity were increased by insulin and reduced by the nonspecific inhibitors of FA transporters phloretin and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS). Perfused hearts from etomoxir-treated lean rats released 221 ± 59 nmol/10 min of FA. Hearts from high-fat-fed lean rats released 366 ± 172 nmol/10 min (P < 0.05). Hearts from obese rats released 744 ± 260 and 1,578 ± 630 nmol/10 min at 8 and 12 weeks of age, respectively. Perfusion with insulin increased FA release by 32%. In vitro and ex vivo findings suggest that nonadipose tissues such as myocardium can export FA when the unoxidized lipid content is excessive.
Abbreviations: FABP, fatty acid-binding protein; FAT/CD36, fatty acid transporter; ZDF, Zucker Diabetic Fatty [rat] Supplementary key words free fatty acid insulin liporegulation triacylglycerol
There is increasing evidence that an intracellular surplus of long chain FAs can cause metabolic trauma to the cells of the heart (1, 2), pancreatic islets (3), and perhaps other organs, so-called "lipotoxicity" (4, 5). Increased triacylglycerol (TG) content in nonadipose organs provides a useful index of the magnitude of the lipid surplus in obesity, a common cause of ectopic lipid deposition in animals (4) and humans (6, 7). Although TGs may not be damaging of themselves (8), their presence in excess may indicate the likelihood that other more harmful lipid derivatives are present. Whenever FA uptake and/or production exceeds the oxidative requirements of a cell, unutilized FA may enter deleterious pathways, such as de novo ceramide formation (9). The resulting apoptosis causes a loss of cardiomyocytes and ß-cells, leading, respectively, to lipotoxic cardiomyopathy (1) and noninsulin-dependent diabetes mellitus (3). It seems likely, therefore, that protective mechanisms against such serious consequences of overnutrition would exist. Compensatory increase in FA oxidation is one protective mechanism that has been proposed (10). There is evidence that, as diet-induced obesity develops, normal adipocytes protect nonadipose tissues from lipotoxicity by secreting adipocytokines, such as leptin and adiponectin, that stimulate FA oxidation (10). A second potentially protective mechanism would be the export of surplus FA from lipid-laden nonadipocytes. The recently proposed secretion of FA as very low density lipoproteins (11) would fall into this category. In the present study, we examined another possible export route, that of reverse FA transport, as a possible exit strategy for the unoxidized lipids. Although export of FA from a nonadipose tissue has never been demonstrated, the concept of reverse FA transport is not new. Myocardial FA release from the human heart has been invoked by several groups to account for discrepancies between arterial and coronary sinus concentrations of radiolabeled and unlabeled FA acids in calculating FA extraction by human (1215), dog (16), and rat (17) hearts. Here we provide direct evidence for the existence of reverse FA transport from both isolated rat cardiomyocytes and from the intact rat heart studied ex vivo. The results strongly imply that, under conditions of intracellular overload, and/or when mitochondrial oxidation is impaired, quantitatively important reverse transport of FA can occur. Moreover, the FA export rate is enhanced by insulin. This raises the interesting possibility of a two-way FA flux. During postprandial hyperinsulinemia, the translocation of FA transporters to the surface of lipid-laden nonadipocytes would permit the efflux of unoxidized FA while suppressing lipolysis in adipocytes. Conversely, during fasting and exercise, when insulin levels are low, the familiar flux of FA from adipocytes to nonadipocytes would occur.
[1-14C]palmitate was obtained from Amersham (Amersham Biosciences, Piscataway, NJ). Essentially FA-free BSA, neutral lipids, phloretin, and DIDS were purchased from Sigma-Aldrich (St. Louis, MO). Etomoxir was obtained from ASAT AG (Switzerland).
Animals
Cardiomyocyte isolation
Reverse FA transport assay
Thin-layer chromatography (TLC)
Langendorff heart perfusion
Determination of myocardial TG content
Quantitative real-time RT-PCR
Statistics
14C-FA export from cultured cardiomyocytes To determine if reverse FA transport is demonstrable in cultured neonatal cardiomyocytes, the cells were incubated with 14C-palmitate with etomoxir added to minimize mitochondrial oxidation (Fig. 1). Twelve hours later, 25% of the label was present in the washed cells in the form of TG, with a small amount present as cholesteryl ester. During a subsequent 3 h period of incubation in fresh medium, 4.5% of the intracellular label appeared outside the cells (Fig. 1A). The radioactivity comigrated with 14C-palmitate on TLC (Fig. 1B). In the absence of etomoxir, both the intracellular accumulation of labeled TG and the extracellular appearance of labeled FA were substantially lower, suggesting that both the intracellular accumulation of FA as TG and reverse FA transport are minimal in cardiomyocytes under normal conditions of unimpeded FA oxidation.
The FA transporter FAT/CD-36 (19) reportedly is translocated by insulin action from an intracellular pool to the plasma membrane, facilitating the transport of long chain FAs into cells (20). When the cardiomyocytes were incubated with insulin in the presence of etomoxir, intracellular TG was increased 2-fold (Fig. 2A), consistent with earlier reports of increased insulin-stimulated FA uptake (20). The appearance of 14C-FA in the medium was also increased 2-fold by insulin (Fig. 2B). Enhancement of both FA import and export by insulin is consistent with insulin-stimulated translocation of a bidirectional transporter that can enhance FA flux into and out of cardiomyocytes, the direction of flow presumably determined by the concentration gradient across the plasma membrane.
Effects of FA transport inhibitors For further evidence of a role of FA transporters in these events, we examined the effects of phloretin, a Ca2+ channel inhibitor that also inhibits FA and glucose transport, and DIDS, a cellular anion channel inhibitor that has been shown to inhibit FAT/CD36 (21). Uptake of 14C-palmitate and export of 14C-FA were reduced by 60% and 66%, respectively, by phloretin and by 62% and 75% by DIDS (Fig. 2B). Although both DIDS and phloretin have pleiotropic actions and are not considered specific inhibitors of proteins involved in FA transport, their effects on FA transport could conceivably involve FA transporter proteins. Taken together, these data are consistent with involvement of FAT/CD-36 in FA flux. To determine if the foregoing results obtained with radiolabeled palmitate are reflected by changes in total TG, we measured the cardiomyocyte TG content biochemically (Fig. 2A). The results were remarkably similar, showing increased TG in etomoxir-treated and insulin-treated cells and a decrease when cells were exposed to phloretin or DIDS.
Time course of FA efflux
FA release in the Langendorff heart perfusion system To determine if the reverse FA transport demonstrated in vitro also occurs in the intact heart, we used the Langendorff heart perfusion system. At 1 h before hanging the heart, the animals were injected with 5 µmol/100 g of body weight of etomoxir to inhibit FA oxidation. This dose, which was three times that employed by Esser's group (22), elicited a rise in plasma FA concentrations from 465 ± 268 µmol to 1,567 ± 645 µmol, presumably reflecting an overall decrease in FA oxidation. Hearts were then excised and perfused for 60 min and effluent was collected at 10 min intervals. We compared the total FA released (concentration x flow) during the second 10 min from wild-type and fatty ZDF hearts. This time period was selected because the effluent was unlikely to contain any residual plasma FA that might contaminate perfusate obtained during the first 10 min of perfusion and yet the condition of the heart would still be optimal. As shown in Fig. 4A, in 12 week old lean wild-type ZDF rats on a normal diet, FA release in the second aliquot was 221 ± 59 nmol/10 min; hearts from similar rats on a high-fat diet for 6 weeks released significantly more FA (366 ± 172 nmol/10 min; P < 0.05).
To determine if the magnitude of outward flux of FA was proportional to the preperfusion myocardial TG content, we measured the mean TG content of unperfused hearts from littermates not selected for perfusion but otherwise identical to the lean and obese rats selected for the perfusion experiments. TG content values are included in Fig. 4A and B. The TG content in unperfused hearts of rats rose on a high-fat diet and was highest after 12 weeks of high-fat feeding. FA release was greater in hearts with a greater TG content (r 2 = 0.86), consistent with the notion that the release of FA into the effluent is related to the magnitude of the lipid excess (Fig. 4C). Neither TG nor glycerol was detected in the effluent. Despite careful removal of epicardial fat prior to perfusing the hearts, it seemed possible that at least some of the measured TG and the FA appearing in the perfusate might be derived from contaminating adipocytes that had escaped detection. To determine if contamination by intramyocardial adipocytes could account for the intergroup differences in TG content and in FA released into the perfusate, we compared the abundance of mRNA of aP2, an adipocyte-binding protein expressed in adipocytes (23). No significant differences in aP2 mRNA were noted (Fig. 4A). Obese ZDF rats have a loss-of-function mutation in their leptin receptor (24) and exhibit a high TG content in their hearts (1). Hearts from obese ZDF rats released 257 ± 74 nmol/10 min of FA without pretreatment with etomoxir (Fig. 4B), whereas FA release from the hearts of wild-type lean ZDF rats was undetectable without etomoxir, even after high-fat feeding (Fig. 4A). After etomoxir treatment, FA release in 8 week old obese ZDF rats was 744 ± 260 nmol/10 min and 1,578 ± 630 nmol/10 min in 12 week old obese ZDF rats (P < 0.01). aP2 mRNA was compared in these obese rats; again, no differences were observed (Fig. 4B). Thus, it seems unlikely that differences in FA released by these hearts were derived from contamination by adipocytes.
Effect of insulin on FA release from perfused hearts
Assessing perfusion-induced myocardial damage Ex vivo perfusion of an organ ultimately results in damage and death of its cells. To exclude structural damage to the heart tissue during the experimental time frames studied, we measured creatine kinase in the perfusate after Langendorff heart perfusion. Creatine kinase was undetectable. Hearts obtained at the end of the perfusion were also examined electron microscopically and no morphological damage was observed (data not shown). We conclude that cardiomyocytes were uninjured during the time frame of our experiments.
FA flux has always been viewed as unidirectional, flowing from adipocytes to nonadipose organs such as heart and skeletal muscle (25). Lipolysis from adipocytes provides a source of fuel for these organs during hypoinsulinemic periods of fasting and/or exercise. Efflux of FA from lean organs to adipocytes and/or liver has never been demonstrated, despite suggestive evidence. In 1969, Most et al. (12) reported that the fractional extraction of labeled FA by the resting human heart was nearly twice that of unlabeled FA, raising the possibility of FA release into the coronary sinus. To our knowledge, no further direct studies were conducted. Not until Bjorkegren et al. (11) described the phenomenon of lipoprotein secretion by the beating heart was the concept of a nonoxidative pathway for the export of unoxidized FA identified. In view of the importance of intracellular lipid homeostasis to the normal function and survival of nonadipocytes, it is not surprising that vital organs such as the heart would have an auxiliary means of self-protection from lipotoxicity, rather than relying entirely on compensatory FA oxidation to reduce a surplus. We hypothesize that under normal circumstances, as insulin levels rise postprandially, plasma FA levels are lowered both by increased adipocyte import and by antilipolytic action on adipocytes. Our data suggest that plasma FA may also be lowered to some degree by increased uptake by insulin-responsive nonadipose tissue. Outward FA transport stimulated by insulin would occur from nonadipocytes only if FA oxidation were reduced and/or intracellular FA influx had created a FA gradient favoring efflux through translocated FA transporters. Although we could detect no extracellular TG or glycerol in the FA-containing media examined, the possibility that FA was derived from TG efflux cannot be categorically ruled out. We now recognize that lipid overload may occur in many disorders commonly encountered in clinical medicine, in addition to rare genetic disorders, such as congenital generalized lipodystrophy, congenital leptin deficiency and leptin resistance. Cardiac steatosis occurs most commonly in diet-induced obesity (7) and in hypoxic states (26); reverse FA transport would be expected to be activated in clinical disorders such as these and whenever FA oxidation is decreased or the influx of FA exceeds the oxidative capacity of the organ. It is clear that insulin stimulates glucose utilization and decreases FA utilization by the heart, but the physiologic role of insulin-stimulated FA uptake in isolated cardiomyocytes is at present unclear. In the present study we examined FA export in vitro and ex vivo. We observed an increase in reverse FA flux whenever FA oxidation was blocked by etomoxir and whenever the TG content of the myocardium was elevated either by overnutrition or by resistance to the antisteatotic action of the liporegulatory hormone, leptin. In both model systems, insulin increased the rate of FA influx and efflux. This is consistent with translocation of a FA transporter, such as the FAT/CD36 (19) to the plasma membrane, after which the direction of FA flux would be determined by the FA gradient. In the presence of insulin, DIDS reduced FA import to 38% of the control and lowered FA export to 25% of the control. These results are consistent with involvement of the Abumrad transporter (19), but more specific inhibitors would be needed to prove this. Palmitoyl CoA condenses with serine in the first step of de novo ceramide formation. Ceramide is considered to be a major factor in the lipoapoptosis that frequently occurs in lipid-overladen cells (2, 10). Thus, palmitate export may play an important protective role in limiting ceramide-induced lipotoxicity and lipoapoptosis. In the etomoxir-treated rats, in which the oxidative pathway had been closed, the increase in FA release induced by insulin was reflected by a reduction in cardiac TG content, evidence that the export of FA can be quantitatively significant. The data suggest the existence of a previously unsuspected insulin-stimulated efflux system through which surplus FA can be exported when compensatory oxidation is reduced. Its implications in human heart disease remain to be explored.
This study was supported by NIDDK-002700-46, the Department of Veterans Affairs Merit Review, and the Jensen Charitable Lead Trust. The authors thank Dr. Victoria Esser for helping with the cardiomyocyte isolation and Dr. Nada Abumrad for providing reagents and suggestions. Manuscript received June 18, 2004 and in revised form August 3, 2004. and in re-revised form August 18, 2004.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||